Galmed Pharmaceuticals LTD. (GLMD) — SEC Filings

Overview

Galmed Pharmaceuticals LTD. (GLMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 14, 2026: Galmed Pharmaceuticals Ltd. filed a 6-K report on April 14, 2026. The filing includes a 6-K form and an exhibit EX-99.1. The company's mailing and business addresses are listed as C/O MEITAR LAW OFFICES in Ramat Gan, Israel.

Sentiment Summary

Across 49 filings, the sentiment breakdown is: 8 bullish, 39 neutral, 2 mixed. The dominant filing sentiment for Galmed Pharmaceuticals LTD. is neutral.

Filing Type Overview

Galmed Pharmaceuticals LTD. (GLMD) has filed 41 6-K, 1 EFFECT, 2 20-F, 5 SC 13G/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (49)

• Galmed Pharmaceuticals Files 6-K Report — 6-K · Apr 14, 2026 Risk: low
  Galmed Pharmaceuticals Ltd. filed a 6-K report on April 14, 2026. The filing includes a 6-K form and an exhibit EX-99.1. The company's mailing and business addr
• Galmed Pharmaceuticals Files 6-K Report — 6-K · Apr 9, 2026 Risk: low
  Galmed Pharmaceuticals Ltd. filed a Form 6-K on April 9, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K fo
• Galmed Pharma's Registration Statement Becomes Effective — EFFECT · Apr 2, 2026 Risk: low
  Galmed Pharmaceuticals Ltd. filed an EFFECT form on April 2, 2026, indicating the effectiveness of a registration statement. The filing relates to Act 33 and ha
• Galmed Pharma's Aramchol Abstract Accepted for HEP-DART 2025 — 6-K · Dec 8, 2025 Risk: medium
  On December 8, 2025, Galmed Pharmaceuticals Ltd. announced that a late-breaking abstract regarding their drug, aramchol, has been accepted for presentation at t
• Galmed Pharma Secures New Patents for Aramchol Combination Therapy — 6-K · Dec 4, 2025 Risk: medium
  On December 4, 2025, Galmed Pharmaceuticals Ltd. announced the grant of new use patents for combining their drug Aramchol with Madrigal Pharmaceuticals' Rezdiff
• 6-K Filing — 6-K · Dec 1, 2025
• Galmed Pharma Files 6-K with Q3 2025 Financials — 6-K · Nov 26, 2025 Risk: low
  Galmed Pharmaceuticals Ltd. filed a 6-K report on November 26, 2025, detailing financial information for the period ending September 30, 2025. The filing includ
• Galmed Pharma Reports Aramchol Study Results — 6-K · Nov 18, 2025 Risk: medium
  On November 18, 2025, Galmed Pharmaceuticals Ltd. announced meaningful top-line results from its AM-001 study of Aramchol Meglumine. The company filed a Form 6-
• Galmed Pharma: Aramchol Combo Shows Promise in GI Cancer Studies — 6-K · Nov 17, 2025 Risk: medium
  On November 17, 2025, Galmed Pharmaceuticals Ltd. announced top-line results from oncology mechanism of action (MoA) studies. The studies showed that a 3-drug c
• Galmed Pharmaceuticals Holds Annual Shareholder Meeting — 6-K · Oct 29, 2025 Risk: low
  On October 29, 2025, Galmed Pharmaceuticals Ltd. held its Annual General Meeting of Shareholders. Shareholders voted on proposals previously outlined in the com
• Galmed Pharma AGM Adjourned Due to Lack of Quorum — 6-K · Oct 28, 2025 Risk: low
  Galmed Pharmaceuticals Ltd. (the "Company") announced that its Annual General Meeting of Shareholders, originally scheduled for October 28, 2025, was adjourned
• Galmed Pharmaceuticals Sets Annual Shareholder Meeting Date — 6-K · Sep 19, 2025 Risk: low
  Galmed Pharmaceuticals Ltd. announced it will hold its Annual General Meeting of Shareholders on October 28, 2025, at 4:00 p.m. Israel time. The meeting will ta
• Galmed Pharma Files 6-K with Q2 2025 Financials — 6-K · Aug 28, 2025 Risk: low
  Galmed Pharmaceuticals Ltd. filed a 6-K report on August 28, 2025, detailing financial information for the period ending June 30, 2025. The filing includes bala
• Galmed Pharma Unveils Digital Asset Strategy, Terminates Deal — 6-K · Aug 25, 2025 Risk: medium
  On August 25, 2025, Galmed Pharmaceuticals Ltd. announced a new digital asset management strategy aimed at improving capital efficiency and increasing sharehold
• Galmed Pharmaceuticals Holds Shareholder Meeting — 6-K · Aug 15, 2025 Risk: low
  On August 15, 2025, Galmed Pharmaceuticals Ltd. held a Special General Meeting of Shareholders where shareholders voted on a proposal previously detailed in a p
• Galmed Pharma Shareholder Meeting Adjourned Due to Lack of Quorum — 6-K · Aug 14, 2025 Risk: low
  Galmed Pharmaceuticals Ltd. held a Special General Meeting of Shareholders on August 14, 2025, but it was adjourned for one day due to a lack of quorum. The mee
• Galmed Pharmaceuticals Sets Shareholder Meeting for August 14 — 6-K · Jul 24, 2025 Risk: low
  Galmed Pharmaceuticals Ltd. announced on July 24, 2025, that it will convene a Special General Meeting of Shareholders on August 14, 2025, at 4:00 p.m. Israel t
• Galmed Pharma Identifies Biomarker for Aramchol Expansion — 6-K · May 27, 2025 Risk: medium
  On May 27, 2025, Galmed Pharmaceuticals Ltd. announced the identification of a proprietary biomarker signature for its drug Aramchol. This discovery is expected
• Galmed Pharma Files 6-K with Q1 2025 Financials — 6-K · May 22, 2025 Risk: low
  Galmed Pharmaceuticals Ltd. filed a Form 6-K on May 22, 2025, reporting its unaudited condensed consolidated financial statements for the three months ended Mar
• Galmed Pharma Reports Aramchol's Anti-Fibrotic Effects in PSC Models — 6-K · May 13, 2025 Risk: medium
  On May 13, 2025, Galmed Pharmaceuticals Ltd. announced significant anti-fibrotic effects of its drug Aramchol in primary sclerosing cholangitis (PSC) models. Th
• Galmed's Aramchol Boosts Bayer's Regorafenib in Cancer Studies — 6-K · May 6, 2025 Risk: medium
  On May 6, 2025, Galmed Pharmaceuticals Ltd. announced positive first-time results from oncology studies. Their drug, Aramchol, significantly enhanced the effect
• Galmed Pharma Signs Term Sheet for Novel Semaglutide Formulation — 6-K · Apr 28, 2025 Risk: medium
  On April 28, 2025, Galmed Pharmaceuticals Ltd. announced it has signed a term sheet for the development of a novel sublingual formulation of Semaglutide. This a
• Galmed Pharma partners with VCU on GI cancer drug resistance — 6-K · Apr 17, 2025 Risk: medium
  On April 17, 2025, Galmed Pharmaceuticals Ltd. announced a new collaboration with VCU to address drug resistance in gastrointestinal (GI) cancers. This partners
• Galmed Pharma unveils Aramchol blood markers — 6-K · Apr 15, 2025 Risk: medium
  On April 15, 2025, Galmed Pharmaceuticals Ltd. announced novel pharmacodynamic blood markers for Aramchol, its SCD1 inhibitor. This development is significant f
• Galmed Pharma Reports Positive Aramchol Meglumine Study Results — 6-K · Apr 10, 2025 Risk: medium
  On April 10, 2025, Galmed Pharmaceuticals Ltd. announced positive Part 1 results from the AM-001 study for Aramchol Meglumine, an enhanced formulation of their
• Galmed Pharmaceuticals Files 2024 Annual Report — 20-F · Apr 2, 2025 Risk: medium
  Galmed Pharmaceuticals Ltd. filed its annual 20-F report for the fiscal year ending December 31, 2024. The company, incorporated in L3 and headquartered in Rama
• Galmed Pharma Secures Patent Extension for Aramchol to 2039 — 6-K · Mar 20, 2025 Risk: low
  On March 20, 2025, Galmed Pharmaceuticals Ltd. announced it has secured a new patent grant for its drug Aramchol. This grant extends the patent protection for A
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Galmed Pharma Files 6-K with Q3 2024 Financials — 6-K · Nov 14, 2024 Risk: low
  Galmed Pharmaceuticals Ltd. filed a Form 6-K on November 14, 2024, reporting its unaudited interim condensed consolidated financial statements for the three and
• Galmed Pharmaceuticals Holds Shareholder Meeting — 6-K · Oct 21, 2024 Risk: low
  On October 21, 2024, Galmed Pharmaceuticals Ltd. held a Special General Meeting of Shareholders where shareholders voted on a proposal previously detailed in a
• Galmed Pharma Shareholder Meeting Adjourned Due to Lack of Quorum — 6-K · Oct 15, 2024 Risk: low
  Galmed Pharmaceuticals Ltd. held a Special General Meeting of Shareholders on October 14, 2024, which was adjourned for one week due to a lack of quorum. The me
• Galmed Pharma Publishes Aramchol Phase 3 Results — 6-K · Sep 25, 2024 Risk: medium
  Galmed Pharmaceuticals Ltd. announced on September 25, 2024, the publication of results from the Phase 3 open-label part of its Aramchol study in the journal He
• SC 13G/A Filing — SC 13G/A · Sep 20, 2024
• Galmed Pharmaceuticals Sets Shareholder Meeting for Oct 14 — 6-K · Sep 20, 2024 Risk: low
  Galmed Pharmaceuticals Ltd. announced on September 20, 2024, that it will hold a Special General Meeting of Shareholders on Monday, October 14, 2024, at 5:00 p.
• Galmed Pharmaceuticals Expands Focus to Cancer & Cardiometabolic Diseases — 6-K · Sep 19, 2024 Risk: medium
  On September 19, 2024, Galmed Pharmaceuticals Ltd. announced an expansion of its business activities to include cancer and major cardiometabolic diseases. This
• Galmed Pharma Regains Nasdaq Listing Compliance — 6-K · Sep 16, 2024 Risk: low
  On September 16, 2024, Galmed Pharmaceuticals Ltd. received notification from the Nasdaq Listing Qualifications Staff that it has regained compliance with the m
• Galmed Pharma Secures Up to $10M Equity Line with Yorkville — 6-K · Aug 30, 2024 Risk: medium
  On August 30, 2024, Galmed Pharmaceuticals Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville). Under this agreement, Galmed h
• Galmed Pharma Files 6-K with Q2 2024 Financials — 6-K · Aug 28, 2024 Risk: low
  Galmed Pharmaceuticals Ltd. filed a 6-K report on August 28, 2024, detailing its financial results for the period ending June 30, 2024. The filing includes fina
• Galmed Pharma to enact 1-for-12 reverse stock split — 6-K · Aug 27, 2024 Risk: medium
  Galmed Pharmaceuticals Ltd. announced on August 27, 2024, that it will implement a 1-for-12 reverse share split. This action will consolidate every twelve ordin
• Galmed Pharmaceuticals Ltd. Holds Annual Shareholder Meeting — 6-K · Jul 18, 2024 Risk: low
  On July 17, 2024, Galmed Pharmaceuticals Ltd. held its Annual General Meeting of Shareholders. Shareholders voted on all proposals that were previously outlined
• Galmed Pharma Annual Meeting Adjourned Due to Lack of Quorum — 6-K · Jul 11, 2024 Risk: low
  Galmed Pharmaceuticals Ltd. convened its Annual General Meeting of Shareholders on July 10, 2024, but it was adjourned for one week due to a lack of quorum. The
• Galmed Pharmaceuticals Sets July 10th Annual Shareholder Meeting — 6-K · Jun 5, 2024 Risk: low
  Galmed Pharmaceuticals Ltd. announced it will hold its Annual General Meeting of Shareholders on Wednesday, July 10, 2024, at 16:00 p.m. Israel time. The meetin
• Galmed Pharma Files Q1 2024 Financials — 6-K · May 30, 2024 Risk: low
  Galmed Pharmaceuticals Ltd. filed a Form 6-K on May 30, 2024, reporting its unaudited condensed consolidated financial statements for the three months ended Mar
• Galmed Pharmaceuticals Ltd. Files 20-F Annual Report — 20-F · Apr 4, 2024 Risk: low
  Galmed Pharmaceuticals Ltd. (GLMD) filed a Foreign Annual Report (20-F) with the SEC on April 4, 2024. Galmed Pharmaceuticals Ltd. filed its annual report on Fo
• Galmed Pharma Faces Nasdaq Bid Price Deadline — 6-K · Mar 19, 2024 Risk: medium
  Galmed Pharmaceuticals Ltd. received a letter in September 2023 from Nasdaq indicating it no longer met the minimum bid price requirement of $1.00 per share. Th
• Galmed Pharma Secures New Patent for NASH Drug Combo — 6-K · Mar 15, 2024 Risk: medium
  On March 15, 2024, Galmed Pharmaceuticals Ltd. announced the grant of a new patent for the combination of their drug Aramchol with Resmetirom (Rezdiffra) for tr
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• G. Yarom Medical Research Ltd. Reports 0% Stake in Galmed Pharma — SC 13G/A · Feb 12, 2024 Risk: low
  G. Yarom Medical Research Ltd. has updated its ownership stake in Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) as of December 31, 2023. The filing, an Amendment N

Risk Profile

Risk Assessment: Of GLMD's 44 recent filings, 0 were flagged as high-risk, 19 as medium-risk, and 25 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Industry Context

Galmed Pharmaceuticals Ltd. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of treatments.

Top Tags

shareholder-meeting (12) · corporate-governance (10) · drug-development (8) · pharmaceuticals (7) · quarterly-results (5) · press-release (5) · 6-K (4) · oncology (4) · filing-update (4) · patent (3)

Key Numbers

• Effectiveness Date: 2026-04-01 — The date the registration statement became effective.
• File Number: 333-289703 — Identifies the specific registration filing.
• Quarterly Financials: Q3 2025 — Updated income statement data for the third quarter of 2025 is presented.
• Reporting Period End Date: 2025-09-30 — The financial data reported covers the period up to this date.
• Financial Period: Q2 2025 — The filing provides financial data for this period.
• Filing Date: 20250828 — The date the report was submitted to the SEC.
• Expansion Potential: $multi-billion — Estimated market size unlocked by the new biomarker signature.
• Fiscal Year End: 2024-12-31 — The period covered by the annual report.
• Patent Expiration: 2039 — Extended patent protection for Aramchol.
• Standby Equity Purchase Facility: $10.0 million — Maximum capital Galmed can raise from Yorkville
• End of Period Date: 2024-06-30 — Specific date for financial reporting
• Reverse Split Ratio: 1-for-12 — Consolidates 12 shares into 1
• Old Par Value: NIS 0.15 — Par value before split
• New Par Value: NIS 1.80 — Par value after split
• Meeting Time: 16:00 p.m. (Israel time) — Time for the reconvened annual general meeting

Forward-Looking Statements

• {"claim":"G. Yarom Medical Research Ltd. will maintain a passive investment stance in Galmed Pharmaceuticals Ltd.","entity":"G. Yarom Medical Research Ltd.","targetDate":"Next 12 months","confidence":"high"}

Related Companies

MDGL · BAYN.DE

Frequently Asked Questions